JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders-Reference-Cited by-同舟云学术

JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders

Published:2007-02-22 Issue:5 Volume:21 Page:1097-1099
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ohyashiki K,Aota Y,Akahane D,Gotoh A,Ohyashiki J H

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404604.pdf

Reference8 articles.

1. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144–1145.

2. Baxter EJ, Scott LM, Campbell PJ, East C, Fouorouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

3. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 779–790.

4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

5. Verstovsek S, Silver RT, Cross NCP, Tefferi A . JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, or less? Leukemia 2006; 20: 2067.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients;Genetics and Molecular Research;2013

2. JAK 2V617F Mutation: Frequency and Relation to Clinical and Laboratory Features of BCR-ABL Negative Myeloproliferative Diseases;International Journal of Hematology and Oncology;2012-06-30

3. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population;BMC Medical Genetics;2012-01-17

4. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?;International Journal of Laboratory Hematology;2010-12-01

5. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia;Internal Medicine Journal;2010-07-30